Population Pharmacokinetics of Tracers: A New Tool for Medical Imaging? Peggy GandiaCyril JaudetDidier Concordet Leading Article 09 July 2016 Pages: 101 - 106
Clinical Pharmacokinetics and Pharmacodynamics of Biologic Therapeutics for Treatment of Systemic Lupus Erythematosus Tian YuElena Y. EnioutinaCatherine M. Sherwin Review Article 06 July 2016 Pages: 107 - 125
Amikacin in Critically Ill Patients: A Review of Population Pharmacokinetic Studies Amélie MarsotRomain GuilhaumouOlivier Blin Review Article 21 June 2016 Pages: 127 - 138
Clinical Pharmacokinetics and Pharmacodynamics of Lenalidomide Nianhang ChenSimon ZhouMaria Palmisano Review Article Open access 28 June 2016 Pages: 139 - 152
Pharmacokinetics and Tolerability of Anti-Hepatitis C Virus Treatment with Ombitasvir, Paritaprevir, Ritonavir, with or Without Dasabuvir, in Subjects with Renal Impairment Amit KhatriSandeep DuttaRajeev M. Menon Original Research Article 07 July 2016 Pages: 153 - 163
Pharmacokinetics of Irinotecan, Oxaliplatin and 5-Fluorouracil During Hepatic Artery Chronomodulated Infusion: A Translational European OPTILIV Study Francis LéviAbdoulaye KarabouéEtienne Chatelut Original Research Article 08 July 2016 Pages: 165 - 177
Pharmacokinetics, Biotransformation, and Excretion of [14C]Etelcalcetide (AMG 416) Following a Single Microtracer Intravenous Dose in Patients with Chronic Kidney Disease on Hemodialysis Raju SubramanianXiaochun ZhuGary L. Skiles Original Research Article Open access 12 August 2016 Pages: 179 - 192
Discrepancies between the Cockcroft–Gault and Chronic Kidney Disease Epidemiology (CKD-EPI) Equations: Implications for Refining Drug Dosage Adjustment Strategies Pierre DelanayeFabrice GuerberHans Pottel Original Research Article 14 July 2016 Pages: 193 - 205
Comment on: “Effect of Age and Renal Function on Idarucizumab Pharmacokinetics and Idarucizumab-Mediated Reversal of Dabigatran Anticoagulant Activity in a Randomized, Double-Blind, Crossover Phase Ib Study” Kirollos S. KamelPaul K. L. ChinMurray L. Barclay Letter to the Editor 20 December 2016 Pages: 207 - 208
Authors’ Reply to Kamel et al.: “Effect of Age and Renal Function on Idarucizumab Pharmacokinetics and Idarucizumab-Mediated Reversal of Dabigatran Anticoagulant Activity in a Randomized, Double-Blind, Crossover Phase Ib Study” Stephan GlundPaul ReillyJoachim Stangier Letter to the Editor Open access 27 December 2016 Pages: 209 - 210
Comment on: “Modeling the Relationship between Exposure to Abiraterone and Prostate-Specific Antigen Dynamics in Patients with Metastatic Castration-Resistant Prostate Cancer” Nuggehally R. Srinivas Letter to the Editor 05 November 2016 Pages: 211 - 212
Author’s Reply to Srinivas: “Modeling the Relationship Between Exposure to Abiraterone and Prostate-Specific Antigen Dynamics in Patients with Metastatic Castration-Resistant Prostate Cancer” Steven XuPeter De Porre Letter to the Editor 05 November 2016 Pages: 213 - 214